We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

NanoString Announces Early Access Agreements with BCM and University of Miami

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

NanoString Technologies has announced the placement of the final Early Access nCounter Analysis Systems prior to the launch of the commercial system at the ABRF2008 (Association of Biomolecular Resource Facilities) meeting in Salt Lake City during February 8-12th.

The two Early Access systems will be placed in the laboratory of Dr. Lisa White at Baylor College of Medicine Microarray Core Facility in Houston, Texas and in the Oncogenomics Core Facility run by Dr. Toumy Guettouche at the University of Miami Sylvester Comprehensive Cancer Center, Miller School of Medicine.

The nCounter Analysis System uses a digital technology that can enable direct multiplexed measurement of gene expression and offers high levels of sensitivity, including detection of fractional fold change differences.

The technology uses molecular barcodes and single molecule imaging to detect and count hundreds of transcripts in a single reaction. The system is comprised of a fully automated sample prep station, a digital analyzer, the CodeSet (molecular barcodes) and all other reagents needed to perform the analysis and is suited for researchers seeking to validate gene expression signatures, working with small amounts of starting material or studying defined gene sets.

“The nCounter Analysis System will be a valuable addition to our facility”, said Dr Toumy Guettouche, who runs the Oncogenomics Core at UM/Sylvester, “the high level of multiplex analysis together with a unique approach in transcript quantification should allow us to complete our gene expression validation projects in a fraction of the time it would take with alternative approaches.”

“We anticipate that the all-in-one feature of the assay will allow our core lab to undertake highly sensitive, expression profiling services with low sample concentration requirements”, said Dr. Lisa White at Baylor College of Medicine.